Mordechai Reuven Reuven Kramer

Prof. Mordechai Reuven Reuven Kramer

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2014 in Respiration
Verified
Journal Article
Open access
PDF file
BVBaruch Vainshelboim
Baruch Vainshelboim
JOJose Oliveira
Jose Oliveira
LYLiora Yehoshua
Liora Yehoshua
IWIsraela Weiss
Israela Weiss
BFBenjamin Daniel Fox
Benjamin Daniel Fox
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating, interstitial lung disease, with few therapeutic options. IPF is characterized by pulmonary restriction, dyspnea, hypoxemia, exercise intolerance and poor quality of life (QOL). Objectives: We aimed to examine the effect of exercise training (ET) on clinical outcomes in IPF patients. Methods: A randomized controlled study included thirty-two IPF patients (aged 68 ± 8 years) who were allocated either to the ET group (n = 15), participating in a 12-week, twice-weekly 60-min supervised ET-based pulmonary rehabilitation program, or to a control group (n = 17) continuing with regular medical treatment alone. Cardiopulmonary exercise test, 6-min walking distance (6MWD) test, 30-second chair-stand test, pulmonary function tests, dyspnea and QOL were assessed at baseline and at the end of the 12-week intervention. Results: Significant differences were observed between the ET and the control groups in raw mean deltas (Δ = post- - pre-intervention): Δ6MWD, 81 m, p < 0.001; ΔVO2 peak, 2.6 ml/kg/min, p = 0.002; Δwork rate, 22 W, p < 0.001; Δanaerobic threshold, 3.1 ml/kg/min, p < 0.001, and ΔFVC % predicted, 6%, p = 0.038. Dyspnea, QOL and 30-second chair-stand were also improved significantly following the program. Conclusions: ET improves exercise tolerance, functional capacity, pulmonary function, dyspnea and QOL in patients with IPF, suggesting a short-term treatment efficacy for clinical improvement, and should be considered the standard care for IPF.

1 August 2005 in The Oncologist
Verified
Journal Article
Open access
PDF file
DSDavid Shitrit
David Shitrit
BZBoris Zingerman
Boris Zingerman
ASAriella Bar-Gil Shitrit
Ariella Bar-Gil Shitrit
DSDekel Shlomi
Dekel Shlomi
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
Levels of tumor markers in pleural effusions may help to establish the diagnosis of pleural malignancy, but the precise diagnostic value of each marker remains unclear. The aim of this study was to assess the diagnostic value of five common pleural fluid tumor markers, carcinoembryonic antigen (CEA), cytokeratin fragment (CYFRA) 21-1, cancer antigen (CA) 15-3, CA 19-9, and CA 125, and to review the literature from the past 15 years. Pleural fluid samples were collected prospectively from 116 patients and assayed for CEA, CYFRA 21-1, CA 15-3, CA 19-9, and CA 125 levels. A MEDLINE search of the English-language literature from the past 15 years was also done.Effusions were classified as benign or malignant on the basis of their definitive pathologic or cytologic diagnoses. The levels of all pleural tumor markers were statistically significantly higher in the malignant group than in the benign group. The marker with the highest accuracy was CEA (85.3%); CA 15-3, CYFRA 21-1, and CA 19-9 had similar accuracies (75.2%, 72.4%, and 71.5%, respectively), and CA 125 had the lowest accuracy (40.5%). On univariate analysis, tumor-marker combinations did not result in a greater accuracy than that of CEA alone. On multivariate logistic regression, CA 15-3 and CYFRA 21-1 were significant predictors of malignancy. Among the nine reports in the literature comparing 11 different tumor markers, CEA, CA 15-3, and CYFRA 21-1 yielded the best results. We conclude that pleural fluid analysis should include CEA for the diagnosis of malignancy. CA 15-3 and CYFRA 21-1 may serve as alternative options.

12 June 2015 in Occupational Medicine
Verified
Journal Article
Closed access
PDF file
OSO. Shtraichman
O. Shtraichman
PBP. D. Blanc
P. D. Blanc
JOJ. E. Ollech
J. E. Ollech
LFL. Fridel
L. Fridel
LFL. Fuks
L. Fuks
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
Background There is a well-established association between inhalational exposure to silica and autoimmune disease. We recently observed an outbreak of silica-related autoimmune disease among synthetic stone construction workers with silicosis referred for lung transplantation assessment. Aims To characterize the rheumatologic complications in silicosis within these highly exposed, clinically well-characterized patients. Methods We systematically reviewed data from all cases of silicosis due to synthetic stone dust referred to our pulmonary institute for lung transplant assessment, which represents the national centre for all such referrals. In addition to silicosis-specific data, we extracted data relevant to the clinical and serological manifestations of autoimmune diseases present in these patients. Results Of 40 patients in our advanced silicosis national data, we identified nine (23%) with findings consistent with various autoimmune diseases. Among these nine, three also had findings consistent with pulmonary alveolar proteinosis. Based on an expected autoimmune disease prevalence of 3% (based on the upper-end estimate for this group of diseases in European international data), the proportion of disease in our group represents a >7-fold excess (prevalence ratio 7.5; 99% confidence interval 2.6–16.7). Conclusions These cases underscore the strong link between silicosis and multiple distinct syndromes of autoimmune diseases. Vigilance is warranted for the recognition of autoimmune complications in persons with known silicosis; so too is consideration of the occupational exposure history in persons presenting with manifestations of autoimmune disease.

1 March 2011 in Chest
Verified
Journal Article
Closed access
PDF file
OFOren Fruchter
Oren Fruchter
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
TDTamir Dagan
Tamir Dagan
YRYael Raviv
Yael Raviv
NANader Abdel-Rahman
Nader Abdel-Rahman
EBElchanan Bruckheimer
Elchanan Bruckheimer

1 November 2012 in Chest
Verified
Journal Article
Closed access
PDF file
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
YRYael Refaely
Yael Refaely
NMNimrod Maimon
Nimrod Maimon
DRDror Rosengarten
Dror Rosengarten
OFOren Fruchter
Oren Fruchter

17 January 2010 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
NRNader Abdel Rahman
Nader Abdel Rahman
OFOren Fruchter
Oren Fruchter
DSDavid Shitrit
David Shitrit
BFBenjamin D Fox
Benjamin D Fox
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
Background: Management of benign tracheal stenosis (BTS) varies with the type and extent of the disease and influenced by the patient's age and general health status, hence we sought to investigate the long-term outcome of patients with BTS that underwent minimally invasive bronchoscopic treatment. Methods: Patients with symptomatic BTS were treated with flexible bronchoscopy therapeutic modalities that included the following: balloon dilatation, laser photo-resection, self-expanding metal stent placement, and High-dose rate endobronchial brachytherapy used in cases of refractory stent-related granulation tissue formation. Results: A total of 115 patients with BTS and various cardiac and respiratory co-morbidities with a mean age of 61 (range 40-88)were treated between January 2001 and January 2009. The underlining etiologies for BTS were post - endotracheal intubation (N = 76) post-tracheostomy (N = 30), Wegener's granulomatosis (N = 2), sarcoidosis (N = 2), amyloidosis (N = 2) and idiopathic BTS (N = 3). The modalities used were: balloon dilatation and laser treatment (N = 98). Stent was placed in 33 patients of whom 28 also underwent brachytherapy. Complications were minor and mostly included granulation tissue formation. The overall success rate was 87%. Over a median follow-up of 51 months (range 10-100 months), 30 patients (26%) died, mostly due to exacerbation of their underlying conditions. Conclusions: BTS in elderly patients with co-morbidities can be safely and effectively treated by flexible bronchoscopic treatment modalities. The use of HDR brachytherapy to treat granulation tissue formation following successful airway restoration is promising.